Literature DB >> 3921288

Studies on a sphingolipid activator protein (SAP-2) in fibroblasts from patients with lysosomal storage diseases, including Niemann-Pick disease Type C.

S Fujibayashi, D A Wenger.   

Abstract

Sphingolipid activator protein-2 (SAP-2) has been found to stimulate the enzymatic hydrolysis of at least three sphingolipids, glucosylceramide, galactosylceramide and sphingomyelin. Using monospecific antibodies against SAP-2 the level of SAP-2 was determined in cultured skin fibroblasts by rocket immunoelectrophoresis. Extracts from 14 controls had 1.03 +/- 0.28 micrograms cross-reactive material/mg solubilized protein and extracts from 46 patients with Niemann-Pick disease Type C had 1.12 +/- 0.26. Extracts from other lysosomal storage diseases, including Gaucher disease, Krabbe disease and Niemann-Pick disease Types A, B and D, had normal or slightly elevated SAP-2 concentrations, while extracts from patients with I-Cell disease had half normal SAP-2 concentration. When the fibroblast extracts were subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis followed by electroblotting and immunochemical staining two major SAP-2 bands with estimated molecular weights of 9000 and 10000 were found. Extracts from patients with I-Cell disease showed only a faint higher molecular weight band. Isoelectric focusing followed by electroblotting and immunochemical staining demonstrated no significant difference in the charge of SAP-2 obtained from different cell lines. In this study we could not demonstrate any change in concentration, size or charge of SAP-2 in fibroblast extracts from Niemann-Pick disease Type C, and we provided evidence that SAP-2 might be subject to post-translational processing similar to that of lysosomal enzymes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921288     DOI: 10.1016/0009-8981(85)90053-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Glucosylceramide and the level of the glucosidase-stimulating proteins.

Authors:  S C Datta; N S Radin
Journal:  Lipids       Date:  1986-11       Impact factor: 1.880

2.  Assignment of the gene for human sphingolipid activator protein-2 (SAP-2) to chromosome 10.

Authors:  S Fujibayashi; F T Kao; C Jones; H Morse; M Law; D A Wenger
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

3.  Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.

Authors:  J M Aerts; W E Donker-Koopman; S Brul; S Van Weely; M C Sa Miranda; J A Barranger; J M Tager; A W Schram
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

4.  Analysis of the multiple forms of Gaucher spleen sphingolipid activator protein 2.

Authors:  B C Paton; A Poulos
Journal:  Biochem J       Date:  1988-08-15       Impact factor: 3.857

5.  Preliminary evidence for a processing error in the biosynthesis of Gaucher activator in mucolipidosis disease types II and III.

Authors:  E Ranieri; B Paton; A Poulos
Journal:  Biochem J       Date:  1986-02-01       Impact factor: 3.857

6.  Role of pH in determining the cell-type-specific residual activity of glucocerebrosidase in type 1 Gaucher disease.

Authors:  S van Weely; M van den Berg; J A Barranger; M C Sa Miranda; J M Tager; J M Aerts
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 7.  Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses.

Authors:  K Harzer; B C Paton; A Poulos; B Kustermann-Kuhn; W Roggendorf; T Grisar; M Popp
Journal:  Eur J Pediatr       Date:  1989-10       Impact factor: 3.183

8.  Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease.

Authors:  V Bradová; F Smíd; B Ulrich-Bott; W Roggendorf; B C Paton; K Harzer
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.